Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP-102 for the Treatment of Symptomatic Gastroparesis in Patients with Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2013
Price :
$35
*
At a glance
- Drugs TZP 102 (Primary)
- Indications Diabetic gastroparesis
- Focus Therapeutic Use
- Sponsors Tranzyme Pharma
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 10 May 2011 Results presented at Digestive Disease Week 2011.
- 10 May 2011 Results presented at the Digestive Disease Week (DDW-2011).